302 related articles for article (PubMed ID: 20589403)
41. Impact of the microgravity environment in a 3-dimensional clinostat on osteoblast- and osteoclast-like cells.
Makihira S; Kawahara Y; Yuge L; Mine Y; Nikawa H
Cell Biol Int; 2008 Sep; 32(9):1176-81. PubMed ID: 18550393
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T
Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059
[TBL] [Abstract][Full Text] [Related]
43. Inhibitory effects of triptolide on titanium particle-induced osteolysis and receptor activator of nuclear factor-κB ligand-mediated osteoclast differentiation.
Kim JA; Ihn HJ; Park JY; Lim J; Hong JM; Kim SH; Kim SY; Shin HI; Park EK
Int Orthop; 2015 Jan; 39(1):173-82. PubMed ID: 25416122
[TBL] [Abstract][Full Text] [Related]
44. Mineral trioxide aggregate (MTA) inhibits osteoclastogenesis and osteoclast activation through calcium and aluminum activities.
Rezende TMB; Ribeiro Sobrinho AP; Vieira LQ; Sousa MGDC; Kawai T
Clin Oral Investig; 2021 Apr; 25(4):1805-1814. PubMed ID: 32789653
[TBL] [Abstract][Full Text] [Related]
45. Ameloblastin attenuates RANKL-mediated osteoclastogenesis by suppressing activation of nuclear factor of activated T-cell cytoplasmic 1 (NFATc1).
Chaweewannakorn W; Ariyoshi W; Okinaga T; Fujita Y; Maki K; Nishihara T
J Cell Physiol; 2019 Feb; 234(2):1745-1757. PubMed ID: 30105896
[TBL] [Abstract][Full Text] [Related]
46. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
47. Ellagic acid blocks RANKL-RANK interaction and suppresses RANKL-induced osteoclastogenesis by inhibiting RANK signaling pathways.
Xu H; Chen F; Liu T; Xu J; Li J; Jiang L; Wang X; Sheng J
Chem Biol Interact; 2020 Nov; 331():109235. PubMed ID: 32971123
[TBL] [Abstract][Full Text] [Related]
48. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
[TBL] [Abstract][Full Text] [Related]
49. Calcitonin-gene-related peptide stimulates stromal cell osteogenic differentiation and inhibits RANKL induced NF-kappaB activation, osteoclastogenesis and bone resorption.
Wang L; Shi X; Zhao R; Halloran BP; Clark DJ; Jacobs CR; Kingery WS
Bone; 2010 May; 46(5):1369-79. PubMed ID: 19962460
[TBL] [Abstract][Full Text] [Related]
50. Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells.
Kim JM; Lee JH; Lee GS; Noh EM; Song HK; Gu DR; Kim SC; Lee SH; Kwon KB; Lee YR
BMC Complement Altern Med; 2017 Mar; 17(1):164. PubMed ID: 28335757
[TBL] [Abstract][Full Text] [Related]
51. Quercetin triggers apoptosis of lipopolysaccharide (LPS)-induced osteoclasts and inhibits bone resorption in RAW264.7 cells.
Guo C; Hou GQ; Li XD; Xia X; Liu DX; Huang DY; Du SX
Cell Physiol Biochem; 2012; 30(1):123-36. PubMed ID: 22759961
[TBL] [Abstract][Full Text] [Related]
52. The effects of Lycii Radicis Cortex on RANKL-induced osteoclast differentiation and activation in RAW 264.7 cells.
Kim JH; Kim EY; Lee B; Min JH; Song DU; Lim JM; Eom JW; Yeom M; Jung HS; Sohn Y
Int J Mol Med; 2016 Mar; 37(3):649-58. PubMed ID: 26848104
[TBL] [Abstract][Full Text] [Related]
53. Enhancement of RANKL-induced MITF-E expression and osteoclastogenesis by TGF-β.
Asai K; Funaba M; Murakami M
Cell Biochem Funct; 2014 Jul; 32(5):401-9. PubMed ID: 24519885
[TBL] [Abstract][Full Text] [Related]
54. AZT enhances osteoclastogenesis and bone loss.
Pan G; Wu X; McKenna MA; Feng X; Nagy TR; McDonald JM
AIDS Res Hum Retroviruses; 2004 Jun; 20(6):608-20. PubMed ID: 15242537
[TBL] [Abstract][Full Text] [Related]
55. Gingipains promote RANKL-induced osteoclastogenesis through the enhancement of integrin β3 in RAW264.7 cells.
Mo W; Luo H; Wu J; Xu N; Zhang F; Qiu Q; Zhu W; Liang M
J Mol Histol; 2020 Apr; 51(2):147-159. PubMed ID: 32193744
[TBL] [Abstract][Full Text] [Related]
56. [The effect of ferric ion on the differentiation of osteoclast and bone resorption].
Jia P; He YF; Gao C; Du HB; Hu ZY; Feng XQ; Li BY; Zhang ZL; Xu YJ; Lin H
Zhonghua Yi Xue Za Zhi; 2012 Aug; 92(31):2214-8. PubMed ID: 23158430
[TBL] [Abstract][Full Text] [Related]
57. A pterostilbene derivative suppresses osteoclastogenesis by regulating RANKL-mediated NFκB and MAPK signaling in RAW264.7 cells.
Nikhil K; Sharan S; Roy P
Pharmacol Rep; 2015 Dec; 67(6):1264-72. PubMed ID: 26481551
[TBL] [Abstract][Full Text] [Related]
58. M-CSF priming of osteoclast precursors can cause osteoclastogenesis-insensitivity, which can be prevented and overcome on bone.
De Vries TJ; Schoenmaker T; Aerts D; Grevers LC; Souza PP; Nazmi K; van de Wiel M; Ylstra B; Lent PL; Leenen PJ; Everts V
J Cell Physiol; 2015 Jan; 230(1):210-25. PubMed ID: 24962140
[TBL] [Abstract][Full Text] [Related]
59. Shikimic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANK/TRAF6 Association and Suppressing NF-κB and MAPK Signaling Pathways.
Chen X; Li X; Zhai X; Zhi X; Cao L; Qin L; Su J
Cell Physiol Biochem; 2018; 51(6):2858-2871. PubMed ID: 30562759
[TBL] [Abstract][Full Text] [Related]
60. SC-19220, antagonist of prostaglandin E2 receptor EP1, inhibits osteoclastogenesis by RANKL.
Tsujisawa T; Inoue H; Nishihara T
J Bone Miner Res; 2005 Jan; 20(1):15-22. PubMed ID: 15619665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
